Haemonetics Corporation (HAE) Earnings History
Steady Earner35 years of earnings data (1992–2026) · Positive but moderate multi-year EPS trajectory
Loading earnings history...
Haemonetics Corporation (HAE) Earnings Overview
As of June 21, 2026, Haemonetics Corporation (HAE) reported trailing twelve-month net income of $97M, reflecting -38.1% year-over-year growth. The company earned $2.11 per diluted share over the past four quarters, with a net profit margin of 7.3%.
Looking at the long-term picture, HAE's 5-year EPS compound annual growth rate (CAGR) stands at +5.8%, showing solid earnings momentum. The company achieved its highest annual net income of $168M in fiscal 2025.
Haemonetics Corporation maintains positive profitability with a gross margin of 55.7%, operating margin of 18.1%, and net margin of 7.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including TFX (-$1.01B net income, -45.4% margin), HOLX ($544M net income, 13.8% margin), ITGR ($142M net income, 5.6% margin), HAE has outperformed on profitability metrics. Compare HAE vs TFX →
HAE Earnings vs Peers
Earnings metrics vs comparable public companies
HAE Historical Earnings Data (1992–2026)
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | $97M | -42.0% | $241M | $2.05 | 7.3% | 18.1% |
| 2025 | $168M | +42.6% | $222M | $3.31 | 12.3% | 16.3% |
| 2024 | $118M | +1.9% | $165M | $2.29 | 9.0% | 12.6% |
| 2023 | $115M | +166.1% | $156M | $2.24 | 9.9% | 13.4% |
| 2022 | $43M | -45.4% | $81M | $0.84 | 4.4% | 8.1% |
| 2021 | $79M | +3.8% | $90M | $1.55 | 9.1% | 10.3% |
| 2020 | $77M | +39.1% | $103M | $1.48 | 7.7% | 10.5% |
| 2019 | $55M | +20.7% | $84M | $1.04 | 5.7% | 8.6% |
| 2018 | $46M | +273.5% | $56M | $0.85 | 5.0% | 6.2% |
| 2017 | -$26M | +52.8% | -$19M | $-0.51 | -3.0% | -2.2% |
| 2016 | -$56M | -429.2% | -$44M | $-1.09 | -6.1% | -4.8% |
| 2015 | $17M | -51.9% | $41M | $0.32 | 1.9% | 4.5% |
| 2014 | $35M | -9.4% | $47M | $0.67 | 3.7% | 5.0% |
| 2013 | $39M | -42.0% | $56M | $0.74 | 4.3% | 6.3% |
| 2012 | $67M | -16.4% | $89M | $1.30 | 9.2% | 12.2% |
| 2011 | $80M | +37.0% | $111M | $1.56 | 11.8% | 16.3% |
| 2010 | $58M | -1.6% | $83M | $1.12 | 9.0% | 12.9% |
| 2009 | $59M | +14.1% | $86M | $1.14 | 9.9% | 14.3% |
| 2008 | $52M | +5.8% | $70M | $0.97 | 10.1% | 13.6% |
| 2007 | $49M | -28.9% | $63M | $0.89 | 10.9% | 14.0% |
| 2006 | $69M | +74.3% | $99M | $1.25 | 16.5% | 23.6% |
| 2005 | $40M | +35.2% | $60M | $0.75 | 10.3% | 15.6% |
| 2004 | $29M | +3.3% | $46M | $0.60 | 8.0% | 12.6% |
| 2003 | $28M | -5.5% | $37M | $0.56 | 8.4% | 11.1% |
| 2002 | $30M | +315.0% | $36M | $0.56 | 9.4% | 11.4% |
| 2001 | $7M | -61.9% | $13M | $0.14 | 2.5% | 4.6% |
| 2000 | $19M | -10.0% | $34M | $0.29 | 6.8% | 12.1% |
| 1999 | $21M | +185.1% | $32M | $0.39 | 7.5% | 11.2% |
| 1998 | -$25M | -175.2% | $31M | $-0.47 | -8.7% | 10.8% |
| 1997 | $33M | -8.1% | $48M | $0.60 | 10.7% | 15.6% |
| 1996 | $36M | +6.8% | $54M | $0.65 | 12.9% | 19.5% |
| 1995 | $34M | +6.7% | $52M | $0.59 | 12.8% | 20.0% |
| 1994 | $32M | +27.0% | $52M | $0.55 | 12.7% | 20.9% |
| 1993 | $25M | +37.8% | $42M | $0.44 | 11.5% | 19.3% |
| 1992 | $18M | - | $30M | $0.32 | 10.2% | 17.0% |
Download Data
Export HAE earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
34+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HAE — Frequently Asked Questions
Quick answers to the most common questions about buying HAE stock.
What is HAE earnings per share (EPS)?
HAE trailing twelve-month (TTM) diluted EPS is $2.11, reflecting -38.1% year-over-year growth. The 5-year EPS CAGR is +5.8%. Complete EPS history from 1992 to 2026 is available in the table on this page.
What is Haemonetics Corporation's net income?
Haemonetics Corporation (HAE) trailing twelve-month net income is $97M as of 2026. Earnings declined -38.1% year-over-year. Haemonetics Corporation has been profitable for 9 consecutive years.
Is HAE profitable?
Yes, HAE is profitable with a TTM net income of $97M and a net profit margin of +7.3%. Haemonetics Corporation has generated profits for 9 consecutive years.
What is HAE's earnings growth rate?
HAE compound annual EPS growth rates (CAGR): 1-Year: -38.1%, 3-Year: -2.9%, 5-Year: +5.8%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1992 to 2026.
What are HAE's profit margins?
Haemonetics Corporation net profit margin is +7.3%, operating margin is +18.1%, and gross margin is +55.7%. Margins are within a typical range for the sector. Return on Equity is +12.0%.
Is HAE growing earnings?
HAE earnings are declining — EPS fell -38.1% year-over-year. TTM net income dropped to $97M. This contrasts with the 5-year CAGR of +5.8%.
What was HAE's best earnings year?
Haemonetics Corporation's highest annual net income on record is $168M, achieved in fiscal year 2025. Earnings history on this page spans 1992 to 2026 and includes all annual and quarterly figures.
What were HAE's earnings last quarter?
HAE's most recent reported quarter was Q4 2026. Net income was $-20M with diluted EPS of $-0.44. For a full breakdown of all quarters, see the quarterly earnings table on this page.